Comparison of hepatic venous pressure gradient and two models of end-stage liver disease for predicting the survival in patients with decompensated liver cirrhosis

Journal of Clinical Gastroenterology

Volumn 46, Issue 10, 2012, Pages 880-886

  Suk, Ki Tae ^a   Kim, Chang Hoon ^b   Park, Seung Ha ^c   Sung, Ho Taik ^d   Choi, Jong Young ^e   Han, Kwang Hyub ^f   Hong, So Hyung ^a   Kim, Dae Yong ^a   Yoon, Jai Hoon ^a   Kim, Yeon Soo ^a   Baik, Gwang Ho ^a   Kim, Jin Bong ^a   Kim, Dong Joon ^a  

^a Hallym University College of Medicine   (South Korea)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c Inje University College of Medicine   (South Korea)

^d STANFORD UNIVERSITY   (United States)

^e Catholic University College of Medicine   (United States)

^f Yonsei University College of Medicine   (South Korea)

Author keywords

end stage liver disease; hepatic veins; mortality; pressure

Indexed keywords

PROPRANOLOL;

ADULT; ARTICLE; CORRELATION ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; END STAGE LIVER DISEASE; FEMALE; FOLLOW UP; HUMAN; MALE; MORTALITY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ADULT; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BLOOD PRESSURE DETERMINATION; END STAGE LIVER DISEASE; FEMALE; HEPATIC VEINS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPRANOLOL; RISK ASSESSMENT; ROC CURVE; SEVERITY OF ILLNESS INDEX; SODIUM; VENOUS PRESSURE;

EID: 84867747981     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31825f2622     Document Type: Article

References (33)

1. Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding-unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. Hepatology. 2008;47:1764-1772.
2. Kim MY, Baik SK, Lee SS. Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol. 2010;16: 347-352.
3. Garcia-Tsao G, Friedman S, Iredale J, et al. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology. 2010;51:1445-1449.
4. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53:762-768.
5. Ripoll C. Hepatic venous pressure gradient and outcomes in cirrhosis. J Clin Gastroenterol. 2007;41(suppl 3):S330-S335.
6. Burroughs AK, Thalheimer U. Hepatic venous pressure gradient in 2010: optimal measurement is key. Hepatology. 2010;51:1894-1896.
7. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864-871.
8. Antaki F, Lukowski A. The model for end-stage liver disease (MELD) predicts survival of liver cirrhosis patients after discharge to hospice. J Clin Gastroenterol. 2007;41:412-415.
9. Freeman RB, Harper AM, Edwards EB. Redrawing organ distribution boundaries: results of a computer-simulated analysis for liver transplantation. Liver Transpl. 2002;8:659-666.
10. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464-470.
11. Coltart I, Austin M, Shawcross DL. Response to "MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation". Gut. 2008;57:1024-1025.
12. Boursier J, Cesbron E, Tropet AL, et al. Comparison and improvement of MELD and Child-Pugh score accuracies for the prediction of 6-month mortality in cirrhotic patients. J Clin Gastroenterol. 2009;43:580-585.
13. Taddei TH, Strazzabosco M. Hepatic venous pressure gradient (HVPG), serum sodium (SNa), and model of end-stage liver disease score (MELD): prognostic significance and correlations. J Clin Gastroenterol. 2007;41:641-643.
14. Hsu CY, Lin HC, Huang YH, et al. Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. Dig Liver Dis. 2010;42:137-142.
15. Thabut D, D'Amico G, Tan P, et al. Diagnostic performance of Baveno IV criteria in cirrhotic patients with upper gastrointestinal bleeding: analysis of the F7 liver-1288 study population. J Hepatol. 2010;53:1029-1034.
16. Bosch J, Abraldes JG, Berzigotti A, et al. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573-582.
17. Ripoll C, Groszmann RJ, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol. 2009;50:923-928.
18. Miraglia R, Luca A, Maruzzelli L, et al. Measurement of hepatic vein pressure gradient in children with chronic liver diseases. J Hepatol. 2010;53:624-629.
19. Wang YW, Huo TI, Yang YY, et al. Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis. J Clin Gastroenterol. 2007;41:706-712.
20. Kumar M, Kumar A, Hissar S, et al. Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus. Liver Int. 2008;28: 690-698.
21. D'Amico G, Garcia-Pagan JC, Luca A, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131: 1611-1624.
22. Suk KT, Kim MY, Park DH, et al. Effect of propranolol on portal pressure and systemic hemodynamics in patients with liver cirrhosis and portal hypertension: a prospective study. Gut Liver. 2007;1:159-164.
23. Turnes J, Garcia-Pagan JC, Abraldes JG, et al. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol. 2006;101:506-512.
24. De BK, Bandyopadhyay K, Das TK, et al. Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am J Gastroenterol. 2003;98:1371-1376.
25. Andreu V, Perello A, Moitinho E, et al. Total effective vascular compliance in patients with cirrhosis. Effects of propranolol. J Hepatol. 2002;36:356-361.
26. De BK, Sen S, Biswas PK, et al. Propranolol in primary and secondary prophylaxis of variceal bleeding among cirrhotics in India: a hemodynamic evaluation. Am J Gastroenterol. 2000;95:2023-2028.
27. Johnson JA, Burlew BS, Stiles RN. Racial differences in betaadrenoceptor-mediated responsiveness. J Cardiovasc Pharmacol. 1995;25:90-96.
28. Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology. 2010;51:2214-2218.
29. Dal-Ros S, Oswald-Mammosser M, Pestrikova T, et al. Losartan prevents portal hypertension-induced, redox-mediated endothelial dysfunction in the mesenteric artery in rats. Gastroenterology. 2010;138:1574-1584.
30. Kemp W, Colman J, Thompson K, et al. Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial. Liver Int. 2009;29:427-433.
31. Kim MY, Cho MY, Baik SK, et al. Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol. 2011;55:1004-1009.
32. Kim MY, Baik SK, Park DH, et al. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study. Liver Int. 2007;27:1103-1110.
33. Kim SU, Kim do Y, Park JY, et al. How can we enhance the performance of liver stiffness measurement using FibroScan in diagnosing liver cirrhosis in patients with chronic hepatitis B? J Clin Gastroenterol. 2010;44:66-71.